Free access to Zolgensma curbed, says Novartis
pharmaphorum
JANUARY 9, 2023
Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1
115 
Let's personalize your content